HLB Genex, Inc. (KOSDAQ:187420)

HLB Genex Revenue

HLB Genex had revenue of 11.33B KRW in the quarter ending June 30, 2026, with 13.22% growth. This brings the company's total for the last twelve months to 45.67B, up 14.42% year-over-year. In the year 2025, HLB Genex had annual revenue of 43.37B with 22.41% growth. That makes HLB Genex the 30,568th largest company in the world by revenue and 1,914th in South Korea.

• Revenue (ttm): 45.67B
• Revenue Growth: +14.42%
• P/S Ratio: 1.75
• Revenue / Employee: 608.93M
• Employees: 75
• Market Cap: 79.82B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Enzyme/Material Business 43.37B 100.0%
• New Drug Development 2.09M 0.0%

By Geography

Chart

• South Korea 25.46B 58.7%
• Netherlands 8.54B 19.7%
• Taiwan 3.31B 7.6%
• Other 2.35B 5.4%
• USA 2.17B 5.0%
• China 806.55M 1.9%
• UK 731.26M 1.7%

Fiscal year ended Dec 31, 2025 See the full HLB Genex breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	43.37B	7.94B	22.41%
Dec 31, 2024	35.43B	8.42B	31.18%
Dec 31, 2023	27.01B	-793.42M	-2.85%
Dec 31, 2022	27.80B	1.93B	7.45%
Dec 31, 2021	25.87B	7.10B	37.85%

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error